Stromal Radiobiology Group
Dr Anna Wilkins’ group is investigating how to target the tumour microenvironment of bladder and prostate cancer to prevent treatment resistance, especially to radiation given with curative intent.
Research and publications in this group
Our research combines comprehensive spatially-resolved profiling of patient tumours from clinical trials with a range of preclinical models for mechanistic interrogation. We have a particular focus on bladder cancer where survival is poor and curative-intent radiotherapy is an important bladder-sparing treatment for patients.
Dr Anna Wilkins
ICR Group Leader / RMH Honorary Consultant:
Stromal Radiobiology
Anna Wilkins is a Clinician Scientist at the ICR and an Honorary Consultant in Clinical Oncology at the Royal Marsden, working in the Prostate and Bladder Research Group.
Researchers in this group
.
OrcID: 0000-0003-3074-6439
Phone: +442071535559
Email: [email protected]
Also on: amy-burley
Location: Sutton
I am a postdoctoral training fellow studying the role of cancer-associated fibroblasts in muscle-invasive bladder cancer. I use multiplex immunofluorescence and digital pathology analysis to quantify the cellular composition and spatial arrangement of cancer-associated fibroblasts in the retrospective clinical trial samples.
.
I am a PhD student investigating the role of myeloid cells in responses to radiotherapy and immunotherapy in muscle-invasive bladder cancer. I will be utilising multiplexed immunofluorescence and transcriptomic techniques on clinical trial samples to gain a wider understanding of the myeloid population interactions within the tumour microenvironment.
.
From enjoying Cancer and Immunology modules in my Imperial College BSc, my Cancer Biology MRes included in vitro CRAF-RAS investigations at the Crick and some unexpected COVID work. My ICR PhD investigated bladder tumour, blood and urine clinical trial samples with genomics, transcriptomics, mIF and flow cytometry, which I’m continuing as a postdoc.
.
I am an HSO/PhD student investigating the roles of cancer-associated fibroblasts in the radiation response in bladder cancer using in vivo and in vitro models. I am interested in assessing radiation-induced changes to the tumour microenvironment with spatial resolution and testing methods that target CAFs to improve radiation responses.
.
I am a Clinical Oncology registrar undertaking an MD focussing on improved biomarker-driven risk stratification and prediction of treatment response in Prostate Cancer. I use digital pathology analysis of diagnostic core biopsy H&E slides from large retrospective studies, along with techniques such as multiplex immunofluorescence and TCR sequencing to evaluate the Prostate Cancer tumour and immune landscape, and longitudinal response to radiotherapy.
Dr Anna Wilkins's group have written 44 publications
Most recent new publication 12/2025
See all their publicationsCurrent vacancies in this group
Higher Scientific Officer
Under the guidance of Anna Wilkins, we are seeking to recruit a Higher Scientific Officer to contribute to collect longitudinal tumour samples and examine how the tumour microenvironment contributes to resistance to PSMA lutetium, and additionally establish how PSMA lutetium drives changes in the tumour microenvironment. The successful candidate will play a key role in tumour collection, plus profiling and analysing the tumour microenvironment. . About you The successful candidate must have: Extensive knowledge of the tumour microenvironment and how to profile it. Experience working with clinical samples BSc (or equivalent) in biological sciences Department/Directorate Information The Stromal Radiobiology Group, led by Anna Wilkins, aims to understand how the tumour microenvironment of urological cancers drives radiotherapy resistance. The group focuses on prostate and bladder cancers with an emphasis on integrating findings from preclinical models and patient samples. The Division of Radiotherapy and Imaging brings together research groups that work on how to use radiation therapy, guided by state-of-the-art imaging techniques, in the most effective way to cure cancer. Our work is based on the central idea that the best outcomes will be achieved by delivering curative radiation doses to tumours, while limiting radiation damage of neighbouring normal tissues. Our therapy often includes adding drug treatments alongside radiation therapy as a means of killing cancer cells more effectively and, at the same time, activating anti-tumour immune responses. Preclinical work includes research that combines radiation therapy with radiation sensitisers and biological response modifiers (for example innate immune activators, immune checkpoint inhibitors and other drugs that modify the tumour microenvironment) to maximise anti-tumour efficacy and give protection against tumour recurrence. Multiple translational clinical studies seek to address these themes through our collaborators in the Royal Marsden Hospital. Overall, our mission is to cure more patients with fewer immediate and long-term side effects of treatment. https://www.icr.ac.uk/research-and-discoveries/icr-divisions/radiotherapy-and-imaging/stromal-radiobiology What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Anna Wilkins via email on [email protected]